The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a huge mover today! About 906,089 shares traded hands. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has risen 0.68% since April 18, 2016 and is uptrending. It has underperformed by 3.75% the S&P500.
The move comes after 5 months positive chart setup for the $462.03M company. It was reported on Nov, 18 by Barchart.com. We have $8.37 PT which if reached, will make NASDAQ:CLDX worth $406.59 million more.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage
Out of 12 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 7 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 58% are positive. Celldex Therapeutics has been the topic of 16 analyst reports since August 11, 2015 according to StockzIntelligence Inc. On Tuesday, March 8 the stock rating was maintained by Cowen & Co with “Outperform”. The rating was downgraded by Guggenheim on Monday, March 7 to “Neutral”. The stock has “Outperform” rating given by Oppenheimer on Tuesday, August 11. The firm earned “Buy” rating on Tuesday, August 11 by TH Capital. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) earned “Buy” rating by Cantor Fitzgerald on Friday, February 26. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) earned “Buy” rating by H.C. Wainwright on Tuesday, March 8. Jefferies maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) rating on Tuesday, August 9. Jefferies has “Hold” rating and $5 price target. The stock has “Market Perform” rating given by Leerink Swann on Monday, March 7. The firm earned “Hold” rating on Tuesday, March 8 by Jefferies. The rating was downgraded by Wedbush on Monday, March 7 to “Neutral”.
According to Zacks Investment Research, “CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.”
More news for Celldex Therapeutics, Inc. (NASDAQ:CLDX) were recently published by: Fool.com, which released: “Why Celldex Therapeutics, Inc. Stock Jumped Higher Again Today” on November 14, 2016. Fool.com‘s article titled: “Better Buy: Celldex Therapeutics, Inc. vs. bluebird bio, Inc.” and published on October 25, 2016 is yet another important article.
CLDX Company Profile
Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Firm is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Firm drug candidates are derived from a set of complementary technologies, which have the ability to utilize the human immune system and enable the creation of therapeutic agents. The Firm is using the technologies to develop targeted immunotherapeutics consist of protein molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). The Company’s Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. The Company’s Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.